Newsy's Latest Health News

The video discusses the latest health headlines, focusing on Gilead Sciences' efforts to increase production of remdesivir, an experimental COVID-19 drug. Gilead plans to produce enough to treat over 140,000 patients by next month and aims for over a million courses by year-end. Early studies show remdesivir helps COVID-19 patients recover 31% faster. New York plans to employ 17,000 contact tracers to track COVID-19 cases, with a goal of 30 tracers per 100,000 residents. The video concludes with acknowledgments to Kaiser Health News.

What is the primary goal of Gilead Sciences regarding remdesivir?

• To sell it exclusively to private clinics

• To stop its production

• To produce enough for 140,000 patients and donate it

• To increase its price

How much faster did COVID-19 patients recover when treated with remdesivir according to early studies?

• 31% faster

• 50% faster

• No difference

• 10% faster

What is Gilead Sciences' production target for remdesivir by the end of the year?

• 1,000,000 treatment courses

• 500,000 treatment courses

• 2,000,000 treatment courses

• 750,000 treatment courses

How many contact tracers does New York plan to employ?

• 5,000

• 10,000

• 17,000

• 25,000

What is the purpose of employing contact tracers in New York?

• To track and isolate COVID-19 cases

• To increase hospital capacity

• To distribute vaccines

• To conduct public health surveys